TY  -  JOUR
AU  -  Cascella, Marco
AU  -  Di Napoli, Raffaela
AU  -  Carbone, Domenico
AU  -  Cuomo, Gaia Francesca
AU  -  Bimonte, Sabrina
AU  -  Ellenga Mbolla, Bertrand Fikahem
AU  -  Muzio, Maria Rosaria
T1  -  Chemotherapy-related cognitive impairment: 
mechanisms, clinical features and research perspectives
PY  -  2018
Y1  -  2018-11-01
DO  -  10.1701/3031.30289
JO  -  Recenti Progressi in Medicina
JA  -  Recenti Prog Med
VL  -  109
IS  -  11
SP  -  523
EP  -  530
PB  -  Il Pensiero Scientifico Editore
SN  -  2038-1840
Y2  -  2026/04/20
UR  -  http://dx.doi.org/10.1701/3031.30289
N2  -  Summary. The term chemotherapy-related cognitive impairment (CRCI), or cognitive dysfunction, or chemo fog, or chemo brain, is referred to a decline in a variety of neuropsychological tasks after chemotherapy, or following other anticancer treatments such as radiation therapy or surgery, in patients with non-central nervous system cancers. Furthermore, several pieces of evidence suggest that clinical manifestations of cognitive impairment may occur in cancer patients, prior to chemotherapy or in those not treated with cancer therapies. In these circumstances, it should be more appropriate to use the term cancer-related cognitive dysfunction. Because there is no consensus about its definition and diagnostic criteria, no specific test for CRCI diagnose exists. Whatever the cause, this manifestation of central nervous system toxicity is of increasing concern as the survival rates for cancer have improved steadily and, in turn, cognitive dysfunction can negatively impact the patients and cancer survivors’ quality of life. The aim of this work is to offer an overview of the topic and recommendations for future research.
ER  -